Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-07

Metabolic correction of hepatoerythropoietic porphyria by retrovirus- mediated gene transfer

Obiettivo



Hepatoerytropoietic porphyria (HEP) is an inherited metabolic disorder characterised by the accumulation of porphyrins resulting from a deficiency in uroporphyrinogen decarboxylase (UROD). This autosomal recessive disorder has been chosen as a model of hematopoietic disease amenable to gene therapy. The disease is severe, starting early in infancy with no specific treatment and gene therapy would represent a great therapeutc improvement. A gene transfer strategy in hematopoiefic cells using retoviral vectors is proposed.
As first step, the efficiency of the viral constructs is tested on human fibroblasts and lymphoblastoid cells which are easy to obtain. At the next step gene transfer is performed in hematopoietic cells obtained from peripheral blood. In the different target cells, the integration of proviral sequences and their expression is checked in short term and long term cultures. In UROD deficient cells, the metabolic correction is analysed in terms of UROD activity and porphyrin accumulation. Finally, the most appropiate viral construct will be used further, ideally in an animal model of the disease, before the design of a human gene therapy clinical protocol.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Invito a presentare proposte

Dati non disponibili

Meccanismo di finanziamento

RGI - Research grants (individual fellowships)

Coordinatore

Université de Bordeaux II
Contributo UE
Nessun dato
Indirizzo
146,Rue Léo Saignat
33076 Bordeaux
Francia
Costo totale
Nessun dato

Partecipanti (1)